[Usefulness of Ospolot in the treatment of epilepsy].
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D004357:Drug Synergism; D004569:Electroencephalography; D004828:Epilepsies, Partial / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000188:drug therapy; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006827:Hydantoins / Q000097:blood / Q000627:therapeutic use; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged; D013843:Thiazines / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D013997:Time Factors
D000927:Anticonvulsants; D006827:Hydantoins; D013843:Thiazines
Przydatność ospolotu w leczeniu padaczki.